{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}],"title":"QTcF <-60 msec change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"}]}],"title":"-60 - < -30 msec change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"65"}]}],"title":"-30 - < 0 msec change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"125"}]}],"title":"0 - 30 msec change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"24"}]}],"title":"> 30 - 60 msec change from BL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"21"}]}],"title":"> 60 msec change from BL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"A12-lead electrocardiogram (ECG) was obtained at baseline (baseline=within 2 weeks prior to randomization) and once between Days 8 and 29. Additional ECGs were done at the Investigator's discretion. ECGs were read centrally. The QT interval corrected with Fridericia formula is presented with categories of changes from baseline (BL) in milliseconds (msec).","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug and had appropriate baseline and on-study ECG data available were analyzed. Participants were analyzed based on the treatment they actually received, not what they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Baseline to Year 2","title":"Number of Participants With Changes From Baseline in QT Interval Corrected With Fridericia Formula (QTcF) up to Year 2 in Treated Participants","type":"SECONDARY","unitOfMeasure":"participants"}